For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged BI 207127, blood-borne infectious disease, Boehringer Ingelheim, Boehringer Ingelheim hepatitis C clinical trials, Dr Reinhard Malin, genoytpe-1 HCV, HCVerso™, HCVerso™ trials, hepatitis C clinical trials, hepatitis C virus, hronic liver disease, liver cancer, Phase IIb interferon-free SOUND-C2 study, Phase IIb SOUND-C3 study, pivotal Phase III HCVerso™1 and 2 trials, Professor Klaus Dugi, protease inhibitor faldaprevir, sustained virological response
For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged atrial fibrillation, atrial fibrillation patient populations, Boehringer Ingelheim, dabigatran etexilate, ESC Congress 2013, ESC Congress 2013 in Amsterdam, European Society of Cardiology, Ingelheim, novel oral anticoagulant (NOAC) Pradaxa®, optimal stroke protection, pivotal RE-LY® trial, Pradaxa®, prevention of stroke and systemic embolism, Professor Klaus Dugi, Sara McClelland
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?